HRP20050593A2 - Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors - Google Patents
Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors Download PDFInfo
- Publication number
- HRP20050593A2 HRP20050593A2 HR20050593A HRP20050593A HRP20050593A2 HR P20050593 A2 HRP20050593 A2 HR P20050593A2 HR 20050593 A HR20050593 A HR 20050593A HR P20050593 A HRP20050593 A HR P20050593A HR P20050593 A2 HRP20050593 A2 HR P20050593A2
- Authority
- HR
- Croatia
- Prior art keywords
- oxo
- hydroxy
- amino
- fluorobenzyl
- tetrahydro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 113
- UBOXAHWUKQXQEH-UHFFFAOYSA-N 2,3,4,6-tetrahydro-1h-pyrido[1,2-a]pyrimidine Chemical class C1=CCN2CCCNC2=C1 UBOXAHWUKQXQEH-UHFFFAOYSA-N 0.000 title abstract description 3
- 229940099797 HIV integrase inhibitor Drugs 0.000 title description 4
- 239000003084 hiv integrase inhibitor Substances 0.000 title description 4
- 208000030507 AIDS Diseases 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 24
- 208000037357 HIV infectious disease Diseases 0.000 claims abstract description 22
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 108010002459 HIV Integrase Proteins 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 20
- -1 4-fluoro-3-methylbenzyl Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 10
- WBQCKUNNRLRPOG-UHFFFAOYSA-N n'-[2-[(4-fluorophenyl)methylcarbamoyl]-3-hydroxy-4-oxo-7,8,9,10-tetrahydro-6h-pyrimido[1,2-a]azepin-10-yl]-n,n,n'-trimethyloxamide Chemical compound CN(C)C(=O)C(=O)N(C)C1CCCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 WBQCKUNNRLRPOG-UHFFFAOYSA-N 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- ZQDWKAJNPJBABY-UHFFFAOYSA-N n'-[2-[(4-fluorophenyl)methylcarbamoyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl]-n,n,n'-trimethyloxamide Chemical compound CN(C)C(=O)C(=O)N(C)C1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 ZQDWKAJNPJBABY-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- MCDBKPBDTVBVTL-UHFFFAOYSA-N 9-[dimethylsulfamoyl(methyl)amino]-n-[(4-fluorophenyl)methyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide Chemical compound CN(C)S(=O)(=O)N(C)C1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 MCDBKPBDTVBVTL-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- BXGKUPHBJWLRPJ-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide Chemical compound N1=C2CCCCN2C(=O)C(O)=C1C(=O)NCC1=CC=C(F)C=C1 BXGKUPHBJWLRPJ-UHFFFAOYSA-N 0.000 claims description 3
- AGXRVRVEFKZWCP-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-9-morpholin-4-yl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide Chemical compound C1CCN2C(=O)C(O)=C(C(=O)NCC=3C=CC(F)=CC=3)N=C2C1N1CCOCC1 AGXRVRVEFKZWCP-UHFFFAOYSA-N 0.000 claims description 3
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical compound NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 claims description 3
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims description 2
- VMWJCFLUSKZZDX-UHFFFAOYSA-N n,n-dimethylmethanamine Chemical compound [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- MCPXZOOZEBNEGJ-UHFFFAOYSA-N n'-[2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-3-hydroxy-4-oxo-7,8,9,10-tetrahydro-6h-pyrimido[1,2-a]azepin-10-yl]-n,n,n'-trimethyloxamide Chemical compound CN(C)C(=O)C(=O)N(C)C1CCCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C(C)=C1 MCPXZOOZEBNEGJ-UHFFFAOYSA-N 0.000 claims 6
- YLIYNHWYALYMOQ-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-9-[methyl-(4-methylpiperazin-1-yl)sulfonylamino]-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide Chemical compound C1CN(C)CCN1S(=O)(=O)N(C)C1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 YLIYNHWYALYMOQ-UHFFFAOYSA-N 0.000 claims 6
- GOIXPYWYXSSRFX-UHFFFAOYSA-N 9-[azetidin-1-ylsulfonyl(methyl)amino]-n-[(4-fluorophenyl)methyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide Chemical compound C1CCN1S(=O)(=O)N(C)C1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 GOIXPYWYXSSRFX-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- COUJNVGGWLUEHF-UHFFFAOYSA-N n'-[2-[(4-fluorophenyl)methylcarbamoyl]-3-hydroxy-8,8-dimethyl-4-oxo-7,9-dihydro-6h-pyrido[1,2-a]pyrimidin-9-yl]-n,n,n'-trimethyloxamide Chemical compound OC=1C(=O)N2CCC(C)(C)C(N(C)C(=O)C(=O)N(C)C)C2=NC=1C(=O)NCC1=CC=C(F)C=C1 COUJNVGGWLUEHF-UHFFFAOYSA-N 0.000 claims 2
- LUKWPQJBONDYSK-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-9-(6-methyl-1,1-dioxo-1,2,6-thiadiazinan-2-yl)-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide Chemical compound O=S1(=O)N(C)CCCN1C1C2=NC(C(=O)NCC=3C=CC(F)=CC=3)=C(O)C(=O)N2CCC1 LUKWPQJBONDYSK-UHFFFAOYSA-N 0.000 claims 2
- IUWUIPCTVGUKAL-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-9-[methyl(morpholin-4-ylsulfonyl)amino]-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide Chemical compound C1COCCN1S(=O)(=O)N(C)C1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 IUWUIPCTVGUKAL-UHFFFAOYSA-N 0.000 claims 2
- SJWPTLITARZLER-UHFFFAOYSA-N 9-[[2-(dimethylsulfamoyl)acetyl]-methylamino]-n-[(4-fluoro-3-methylphenyl)methyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide Chemical compound CN(C)S(=O)(=O)CC(=O)N(C)C1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C(C)=C1 SJWPTLITARZLER-UHFFFAOYSA-N 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- FHMHJNJYVZSGOD-UHFFFAOYSA-N n'-[2-[(3-chloro-4-methylphenyl)methylcarbamoyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl]-n,n,n'-trimethyloxamide Chemical compound CN(C)C(=O)C(=O)N(C)C1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(C)C(Cl)=C1 FHMHJNJYVZSGOD-UHFFFAOYSA-N 0.000 claims 1
- QMHNSONWMFDIOU-UHFFFAOYSA-N n'-[2-[(3-chlorophenyl)methylcarbamoyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl]-n,n,n'-trimethyloxamide Chemical compound CN(C)C(=O)C(=O)N(C)C1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=CC(Cl)=C1 QMHNSONWMFDIOU-UHFFFAOYSA-N 0.000 claims 1
- SJVFREKFBRXASI-UHFFFAOYSA-N n'-[2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-3-hydroxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl]-n,n,n'-trimethyloxamide Chemical compound CN(C)C(=O)C(=O)N(C)C1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C(C)=C1 SJVFREKFBRXASI-UHFFFAOYSA-N 0.000 claims 1
- GJDMGRQVNYSRDY-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-9-[methyl(pyrrolidin-1-ylsulfonyl)amino]-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide Chemical compound C1CCCN1S(=O)(=O)N(C)C1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 GJDMGRQVNYSRDY-UHFFFAOYSA-N 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 230000010076 replication Effects 0.000 abstract description 8
- 239000002955 immunomodulating agent Substances 0.000 abstract description 7
- 239000003112 inhibitor Substances 0.000 abstract description 7
- 229940121354 immunomodulator Drugs 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 6
- 229960005486 vaccine Drugs 0.000 abstract description 4
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 229940042443 other antivirals in atc Drugs 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 79
- 239000000243 solution Substances 0.000 description 66
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 59
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 55
- 239000000203 mixture Substances 0.000 description 55
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 47
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 39
- 239000000047 product Substances 0.000 description 38
- 239000002904 solvent Substances 0.000 description 38
- 238000000034 method Methods 0.000 description 35
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- 235000019439 ethyl acetate Nutrition 0.000 description 32
- 241000725303 Human immunodeficiency virus Species 0.000 description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 102100034343 Integrase Human genes 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000012267 brine Substances 0.000 description 16
- 239000012043 crude product Substances 0.000 description 16
- 239000003480 eluent Substances 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- 239000012071 phase Substances 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 238000004007 reversed phase HPLC Methods 0.000 description 10
- 108010061833 Integrases Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 150000004702 methyl esters Chemical class 0.000 description 9
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 9
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 8
- 101710203526 Integrase Proteins 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 235000011007 phosphoric acid Nutrition 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- XPNODRGEKBEUOO-UHFFFAOYSA-N methyl 3-hydroxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxylate Chemical compound C1CCCN2C(=O)C(O)=C(C(=O)OC)N=C21 XPNODRGEKBEUOO-UHFFFAOYSA-N 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 6
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
- FBDGJZXFKQZWLX-UHFFFAOYSA-N 4,6-bis(methylsulfonyl)pyrimidine Chemical compound CS(=O)(=O)C1=CC(S(C)(=O)=O)=NC=N1 FBDGJZXFKQZWLX-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 229960005475 antiinfective agent Drugs 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 239000004030 hiv protease inhibitor Substances 0.000 description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
- SQEFGLOWXIZRKE-UHFFFAOYSA-N methyl 3-benzoyloxy-10-bromo-4-oxo-7,8,9,10-tetrahydro-6h-pyrimido[1,2-a]azepine-2-carboxylate Chemical compound COC(=O)C=1N=C2C(Br)CCCCN2C(=O)C=1OC(=O)C1=CC=CC=C1 SQEFGLOWXIZRKE-UHFFFAOYSA-N 0.000 description 4
- KJHZXESGIMLERK-UHFFFAOYSA-N methyl 3-benzoyloxy-9-bromo-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxylate Chemical compound COC(=O)C=1N=C2C(Br)CCCN2C(=O)C=1OC(=O)C1=CC=CC=C1 KJHZXESGIMLERK-UHFFFAOYSA-N 0.000 description 4
- 239000012038 nucleophile Substances 0.000 description 4
- 230000001566 pro-viral effect Effects 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- LCLCMDMTYLSGGV-UHFFFAOYSA-N 1-hydroxypiperidin-2-imine;hydrochloride Chemical compound Cl.ON1CCCCC1=N LCLCMDMTYLSGGV-UHFFFAOYSA-N 0.000 description 3
- DRKMDRWHVNAXBW-UHFFFAOYSA-N 1-phenylmethoxypiperidin-2-imine;hydrochloride Chemical compound Cl.N=C1CCCCN1OCC1=CC=CC=C1 DRKMDRWHVNAXBW-UHFFFAOYSA-N 0.000 description 3
- 206010001513 AIDS related complex Diseases 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 101100170601 Drosophila melanogaster Tet gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- BWNCPYNIWSSQBQ-CMDGGOBGSA-N dimethyl (e)-2-(3,4,5,6-tetrahydro-2h-azepin-7-ylamino)oxybut-2-enedioate Chemical compound COC(=O)\C=C(C(=O)OC)\ON=C1CCCCCN1 BWNCPYNIWSSQBQ-CMDGGOBGSA-N 0.000 description 3
- BWNCPYNIWSSQBQ-HJWRWDBZSA-N dimethyl (z)-2-(3,4,5,6-tetrahydro-2h-azepin-7-ylamino)oxybut-2-enedioate Chemical compound COC(=O)\C=C(C(=O)OC)/ON=C1CCCCCN1 BWNCPYNIWSSQBQ-HJWRWDBZSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- RWGFKTVRMDUZSP-UHFFFAOYSA-N isopropyl-benzene Natural products CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 3
- VZUVVNQOCOPLJM-UHFFFAOYSA-N methyl 2-(2-methoxy-2-oxoethyl)-5,6,7,8-tetrahydro-[1,2,4]oxadiazolo[2,3-a]pyridine-2-carboxylate Chemical compound C1CCCC2=NC(CC(=O)OC)(C(=O)OC)ON21 VZUVVNQOCOPLJM-UHFFFAOYSA-N 0.000 description 3
- ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PMFJIAMYWRXMHN-UHFFFAOYSA-N tert-butyl n-(4-cyanobutyl)-n-phenylmethoxycarbamate Chemical compound N#CCCCCN(C(=O)OC(C)(C)C)OCC1=CC=CC=C1 PMFJIAMYWRXMHN-UHFFFAOYSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- IIBCXWODTDZCGF-UHFFFAOYSA-N 1-phenylmethoxyazepan-2-imine Chemical compound N=C1CCCCCN1OCC1=CC=CC=C1 IIBCXWODTDZCGF-UHFFFAOYSA-N 0.000 description 2
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- NUGSWHXKRIAFOV-UHFFFAOYSA-N dimethyl 2-oxo-3-phenylmethoxybutanedioate Chemical compound COC(=O)C(=O)C(C(=O)OC)OCC1=CC=CC=C1 NUGSWHXKRIAFOV-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HIXJALCCWDHEAR-UHFFFAOYSA-N methyl 3-benzoyloxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxylate Chemical compound COC(=O)C=1N=C2CCCCN2C(=O)C=1OC(=O)C1=CC=CC=C1 HIXJALCCWDHEAR-UHFFFAOYSA-N 0.000 description 2
- NFOIRGVGUOENDH-UHFFFAOYSA-N methyl 3-benzoyloxy-4-oxo-7,8,9,10-tetrahydro-6h-pyrimido[1,2-a]azepine-2-carboxylate Chemical compound COC(=O)C=1N=C2CCCCCN2C(=O)C=1OC(=O)C1=CC=CC=C1 NFOIRGVGUOENDH-UHFFFAOYSA-N 0.000 description 2
- BERNBOUHVFAAAE-PUODRLBUSA-N methyl 3-hydroxy-4-oxo-10-[[(1r)-1-phenylethyl]amino]-7,8,9,10-tetrahydro-6h-pyrimido[1,2-a]azepine-2-carboxylate Chemical compound C1([C@@H](C)NC2C3=NC(=C(C(=O)N3CCCC2)O)C(=O)OC)=CC=CC=C1 BERNBOUHVFAAAE-PUODRLBUSA-N 0.000 description 2
- IGYWDTYEDKKTLK-UHFFFAOYSA-N methyl 3-hydroxy-4-oxo-7,8,9,10-tetrahydro-6h-pyrimido[1,2-a]azepine-2-carboxylate Chemical compound C1CCCCN2C(=O)C(O)=C(C(=O)OC)N=C21 IGYWDTYEDKKTLK-UHFFFAOYSA-N 0.000 description 2
- IWOUDGARURIUCJ-UHFFFAOYSA-N methyl 4-oxo-3-phenylmethoxy-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxylate Chemical compound COC(=O)C=1N=C2CCCCN2C(=O)C=1OCC1=CC=CC=C1 IWOUDGARURIUCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QUHQMUZDZWHIPO-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-9-(methylamino)-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide Chemical compound CNC1CCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 QUHQMUZDZWHIPO-UHFFFAOYSA-N 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 2
- 229950010765 pivalate Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- MZNBNPWFHGWAGH-UHFFFAOYSA-N tert-butyl n-phenylmethoxycarbamate Chemical compound CC(C)(C)OC(=O)NOCC1=CC=CC=C1 MZNBNPWFHGWAGH-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000006276 transfer reaction Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- XUKFSXNWRWHCEQ-UHFFFAOYSA-N 4-chloropentanenitrile Chemical compound CC(Cl)CCC#N XUKFSXNWRWHCEQ-UHFFFAOYSA-N 0.000 description 1
- PHOSWLARCIBBJZ-UHFFFAOYSA-N 6-bromohexanenitrile Chemical compound BrCCCCCC#N PHOSWLARCIBBJZ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000807 Acute HIV infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 108010064899 Human Immunodeficiency Virus Ribonuclease H Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010069803 Injury associated with device Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- CBSOFSBFHDQRLV-UHFFFAOYSA-N N-methylbenzylamine hydrochloride Chemical compound [Cl-].C[NH2+]CC1=CC=CC=C1 CBSOFSBFHDQRLV-UHFFFAOYSA-N 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- KITGYVIOYOCIIE-QNMAEOQASA-N [(z)-hex-3-enyl] (e)-but-2-enoate Chemical compound CC\C=C/CCOC(=O)\C=C\C KITGYVIOYOCIIE-QNMAEOQASA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940124425 anti-infective immunomodulator Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000002592 cumenyl group Chemical group C1(=C(C=CC=C1)*)C(C)C 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- GDHLKBUFKLFPBF-UHFFFAOYSA-N ethyl 6-(phenylmethoxyamino)hexanoate Chemical compound CCOC(=O)CCCCCNOCC1=CC=CC=C1 GDHLKBUFKLFPBF-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PUYCICVJCRLABY-UHFFFAOYSA-N heptane;oxolane Chemical compound C1CCOC1.CCCCCCC PUYCICVJCRLABY-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- QNEIZSSWCVSZOS-UHFFFAOYSA-N methyl 2-phenylmethoxyacetate Chemical compound COC(=O)COCC1=CC=CC=C1 QNEIZSSWCVSZOS-UHFFFAOYSA-N 0.000 description 1
- DTEOUDKGIWFDEO-UHFFFAOYSA-N methyl 3-hydroxy-9-(methylamino)-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxylate Chemical compound CNC1CCCN2C1=NC(C(=O)OC)=C(O)C2=O DTEOUDKGIWFDEO-UHFFFAOYSA-N 0.000 description 1
- RSNVSNOSNVCVTR-UHFFFAOYSA-N methyl 9-[benzyl(methyl)amino]-3-hydroxy-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxylate;hydrochloride Chemical compound Cl.C1CCN2C(=O)C(O)=C(C(=O)OC)N=C2C1N(C)CC1=CC=CC=C1 RSNVSNOSNVCVTR-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
- PPOHPUOKXMNCCI-UHFFFAOYSA-N n-(3,4,5,6-tetrahydro-2h-azepin-7-yl)hydroxylamine Chemical compound ONC1=NCCCCC1 PPOHPUOKXMNCCI-UHFFFAOYSA-N 0.000 description 1
- HIOPZDBGXHDCMB-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-10-(methylamino)-4-oxo-7,8,9,10-tetrahydro-6h-pyrimido[1,2-a]azepine-2-carboxamide Chemical compound CNC1CCCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 HIOPZDBGXHDCMB-UHFFFAOYSA-N 0.000 description 1
- WZUWQZYLHJCNOO-OQHSHRKDSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-10-[methyl-[(1r)-1-phenylethyl]amino]-4-oxo-7,8,9,10-tetrahydro-6h-pyrimido[1,2-a]azepine-2-carboxamide Chemical compound CN([C@H](C)C=1C=CC=CC=1)C1CCCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 WZUWQZYLHJCNOO-OQHSHRKDSA-N 0.000 description 1
- WKDJVAMTCVRQSI-QRIPLOBPSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-4-oxo-10-[[(1r)-1-phenylethyl]amino]-7,8,9,10-tetrahydro-6h-pyrimido[1,2-a]azepine-2-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C1CCCCN(C(C=2O)=O)C1=NC=2C(=O)NCC1=CC=C(F)C=C1 WKDJVAMTCVRQSI-QRIPLOBPSA-N 0.000 description 1
- XMIPAKWCYIZLFV-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-hydroxy-9-morpholin-4-yl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidine-2-carboxamide;hydrochloride Chemical compound Cl.C1CCN2C(=O)C(O)=C(C(=O)NCC=3C=CC(F)=CC=3)N=C2C1N1CCOCC1 XMIPAKWCYIZLFV-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-L oxaloacetate(2-) Chemical compound [O-]C(=O)CC(=O)C([O-])=O KHPXUQMNIQBQEV-UHFFFAOYSA-L 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 1
- 150000008518 pyridopyrimidines Chemical class 0.000 description 1
- IDXKTTNFXPPXJY-UHFFFAOYSA-N pyrimidin-1-ium;chloride Chemical compound Cl.C1=CN=CN=C1 IDXKTTNFXPPXJY-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- XJBFPQUKNPHLBX-UHFFFAOYSA-N tert-butyl n-(5-cyanopentyl)-n-phenylmethoxycarbamate Chemical compound N#CCCCCCN(C(=O)OC(C)(C)C)OCC1=CC=CC=C1 XJBFPQUKNPHLBX-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43683002P | 2002-12-27 | 2002-12-27 | |
| US52877603P | 2003-12-12 | 2003-12-12 | |
| PCT/GB2003/005543 WO2004058757A1 (en) | 2002-12-27 | 2003-12-18 | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050593A2 true HRP20050593A2 (en) | 2006-03-31 |
Family
ID=32685467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050593A HRP20050593A2 (en) | 2002-12-27 | 2005-06-24 | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7414045B2 (zh) |
| EP (1) | EP1578748B1 (zh) |
| JP (1) | JP4733986B2 (zh) |
| KR (1) | KR20050087865A (zh) |
| CN (1) | CN100343253C (zh) |
| AT (1) | ATE481401T1 (zh) |
| AU (2) | AU2003292437A1 (zh) |
| BR (1) | BR0317749A (zh) |
| CA (1) | CA2509554C (zh) |
| DE (1) | DE60334248D1 (zh) |
| EC (1) | ECSP055890A (zh) |
| HR (1) | HRP20050593A2 (zh) |
| IS (1) | IS7892A (zh) |
| MA (1) | MA27583A1 (zh) |
| MX (1) | MXPA05007010A (zh) |
| NO (1) | NO20053624L (zh) |
| NZ (1) | NZ540729A (zh) |
| PL (1) | PL377354A1 (zh) |
| RU (1) | RU2329265C2 (zh) |
| WO (2) | WO2004058756A1 (zh) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004062613A2 (en) * | 2003-01-13 | 2004-07-29 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| US7435735B2 (en) | 2003-10-20 | 2008-10-14 | Merck & Co., Inc. | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors |
| AR046938A1 (es) * | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) * | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7173022B2 (en) | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7192948B2 (en) * | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| WO2006060225A2 (en) * | 2004-11-23 | 2006-06-08 | Merck & Co., Inc. | Process for asymmetric synthesis of hexahydropyrimido[1,2-a] azepine-2-carboxamides and related compounds |
| KR20070085702A (ko) * | 2004-12-03 | 2007-08-27 | 머크 앤드 캄파니 인코포레이티드 | Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도 |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| BRPI0518781A2 (pt) * | 2004-12-03 | 2008-12-09 | Merck & Co Inc | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto |
| EP1819323B2 (en) | 2004-12-03 | 2023-03-22 | Merck Sharp & Dohme Corp. | Pharmaceutical composition containing an anti-nucleating agent |
| ATE516026T1 (de) * | 2005-02-21 | 2011-07-15 | Shionogi & Co | Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung |
| CN101146811B (zh) * | 2005-03-31 | 2012-01-11 | P.安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
| PL3045206T3 (pl) | 2005-04-28 | 2018-08-31 | Viiv Healthcare Company | Wielopierścieniowe pochodne karbamoilopirydonu wykazujące aktywność inhibitorową wobec integrazy HIV |
| AU2006266167A1 (en) | 2005-06-30 | 2007-01-11 | Wyeth | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation |
| US7494984B2 (en) * | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| JP5094725B2 (ja) * | 2005-10-04 | 2012-12-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Ｈｉｖインテグラーゼ阻害剤 |
| TW200800988A (en) | 2005-10-27 | 2008-01-01 | Shionogi & Amp Co Ltd | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
| EP1942736A2 (en) * | 2005-10-27 | 2008-07-16 | Merck & Co., Inc. | Hiv integrase inhibitors |
| WO2007059125A2 (en) * | 2005-11-15 | 2007-05-24 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| WO2007058646A1 (en) * | 2005-11-15 | 2007-05-24 | Bristol-Myers Squibb Company | Hiv integrase inhibitors: cyclic pyrimidinone compounds |
| US7902182B2 (en) * | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) * | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2007064316A1 (en) * | 2005-11-30 | 2007-06-07 | Bristol-Myers Squibb Company | Bicyclic heterocycles as hiv integrase inhibitors |
| US20070129379A1 (en) * | 2005-12-01 | 2007-06-07 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| US20090136570A1 (en) * | 2006-01-20 | 2009-05-28 | Bhagwant Rege | Taste-Masked Tablets and Granules |
| WO2007143446A1 (en) * | 2006-05-30 | 2007-12-13 | Bristol-Myers Squibb Company | Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors |
| US7893055B2 (en) * | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7763630B2 (en) * | 2007-06-06 | 2010-07-27 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8129398B2 (en) * | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2010042392A2 (en) * | 2008-10-06 | 2010-04-15 | Merck & Co., Inc. | Hiv integrase inhibitors |
| US8624023B2 (en) * | 2008-12-11 | 2014-01-07 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| CA2766909C (fr) * | 2009-07-02 | 2018-06-05 | Sanofi | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one,leur preparation et leur utilisation pharmaceutique |
| AU2010305805B2 (en) | 2009-10-13 | 2014-04-03 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors |
| US8383639B2 (en) | 2009-10-15 | 2013-02-26 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| AU2010313571B2 (en) | 2009-10-26 | 2014-07-31 | Merck Sharp & Dohme Llc | Solid pharmaceutical compositions containing an integrase inhibitor |
| JP5739517B2 (ja) | 2010-04-02 | 2015-06-24 | ヤンセン・アールアンドデイ・アイルランド | 大環状インテグラーゼ阻害剤 |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| EA029473B1 (ru) | 2011-12-15 | 2018-03-30 | Новартис Аг | Применение ингибиторов pi3k для лечения острой и церебральной малярии |
| US9714243B2 (en) | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
| WO2014172188A2 (en) | 2013-04-16 | 2014-10-23 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
| SI2997033T1 (en) | 2013-05-17 | 2018-04-30 | Merck Sharp & Dohme Corp. | FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS |
| EP3008044B1 (en) | 2013-06-13 | 2018-11-21 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| ES2768658T3 (es) | 2013-09-27 | 2020-06-23 | Merck Sharp & Dohme | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del VIH |
| WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| WO2017087257A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
| US10544155B2 (en) | 2015-12-15 | 2020-01-28 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors |
| WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| RU2749043C2 (ru) | 2016-12-02 | 2021-06-03 | Мерк Шарп И Доум Корп. | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| WO2018140368A1 (en) | 2017-01-26 | 2018-08-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
| KR20210015922A (ko) | 2018-05-31 | 2021-02-10 | 시오노기 앤드 컴파니, 리미티드 | 다환성 카바모일피리돈 유도체 |
| MX2020012185A (es) | 2018-05-31 | 2021-01-29 | Shionogi & Co | Derivado policiclico de piridona. |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306891B1 (en) | 1998-06-03 | 2001-10-23 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6380249B1 (en) | 1998-06-03 | 2002-04-30 | Merck & Co., Inc. | HIV integrase inhibitors |
| US6262055B1 (en) | 1998-06-03 | 2001-07-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| EP1196384A4 (en) | 1999-06-25 | 2002-10-23 | Merck & Co Inc | 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS |
| JP2003535865A (ja) | 2000-06-07 | 2003-12-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼインヒビターおよびその使用 |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| CA2321348A1 (en) * | 2000-09-27 | 2002-03-27 | Blaise Magloire N'zemba | Aromatic derivatives with hiv integrase inhibitory properties |
| CA2425067A1 (en) | 2000-10-12 | 2002-05-10 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors |
| CA2425625A1 (en) | 2000-10-12 | 2002-07-18 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| ES2287170T3 (es) | 2000-10-12 | 2007-12-16 | MERCK & CO., INC. | Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa. |
| DE60138635D1 (de) | 2000-10-12 | 2009-06-18 | Merck & Co Inc | Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase |
| KR20100087209A (ko) | 2001-08-10 | 2010-08-03 | 시오노기세이야쿠가부시키가이샤 | 항바이러스제 |
| RS51542B (sr) | 2001-10-26 | 2011-06-30 | Istituto Di Ricerche Di Biologia Molecolare P.Angeletti Spa. | N-supstituisani hidroksipirimidinon karboksamidni inhibitori hiv integraze |
| WO2003035076A1 (en) | 2001-10-26 | 2003-05-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| DE60315796T2 (de) | 2002-01-17 | 2008-06-05 | Merck & Co., Inc. | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen |
| AU2003248872A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| WO2004062613A2 (en) | 2003-01-13 | 2004-07-29 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| AR046938A1 (es) * | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
-
2003
- 2003-12-18 MX MXPA05007010A patent/MXPA05007010A/es active IP Right Grant
- 2003-12-18 AT AT03768014T patent/ATE481401T1/de not_active IP Right Cessation
- 2003-12-18 CN CNB2003801099211A patent/CN100343253C/zh not_active Expired - Fee Related
- 2003-12-18 JP JP2004563339A patent/JP4733986B2/ja not_active Expired - Fee Related
- 2003-12-18 AU AU2003292437A patent/AU2003292437A1/en not_active Abandoned
- 2003-12-18 WO PCT/GB2003/005536 patent/WO2004058756A1/en active Application Filing
- 2003-12-18 US US10/540,449 patent/US7414045B2/en active Active
- 2003-12-18 PL PL377354A patent/PL377354A1/pl not_active Application Discontinuation
- 2003-12-18 WO PCT/GB2003/005543 patent/WO2004058757A1/en not_active Application Discontinuation
- 2003-12-18 EP EP03768014A patent/EP1578748B1/en not_active Expired - Lifetime
- 2003-12-18 RU RU2005123807/04A patent/RU2329265C2/ru not_active IP Right Cessation
- 2003-12-18 CA CA2509554A patent/CA2509554C/en not_active Expired - Fee Related
- 2003-12-18 KR KR1020057012028A patent/KR20050087865A/ko not_active Application Discontinuation
- 2003-12-18 AU AU2003292436A patent/AU2003292436B2/en not_active Ceased
- 2003-12-18 NZ NZ540729A patent/NZ540729A/en unknown
- 2003-12-18 BR BR0317749-1A patent/BR0317749A/pt not_active IP Right Cessation
- 2003-12-18 DE DE60334248T patent/DE60334248D1/de not_active Expired - Lifetime
-
2005
- 2005-06-13 IS IS7892A patent/IS7892A/is unknown
- 2005-06-23 EC EC2005005890A patent/ECSP055890A/es unknown
- 2005-06-24 HR HR20050593A patent/HRP20050593A2/hr not_active Application Discontinuation
- 2005-07-21 MA MA28407A patent/MA27583A1/fr unknown
- 2005-07-26 NO NO20053624A patent/NO20053624L/no not_active Application Discontinuation
-
2008
- 2008-03-12 US US12/075,514 patent/US7968553B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003292436A1 (en) | 2004-07-22 |
| ATE481401T1 (de) | 2010-10-15 |
| CA2509554C (en) | 2011-02-01 |
| CA2509554A1 (en) | 2004-07-15 |
| ECSP055890A (es) | 2005-09-20 |
| AU2003292437A1 (en) | 2004-07-22 |
| DE60334248D1 (de) | 2010-10-28 |
| US7968553B2 (en) | 2011-06-28 |
| CN1753892A (zh) | 2006-03-29 |
| MXPA05007010A (es) | 2005-08-18 |
| MA27583A1 (fr) | 2005-10-03 |
| EP1578748A1 (en) | 2005-09-28 |
| WO2004058756A1 (en) | 2004-07-15 |
| RU2329265C2 (ru) | 2008-07-20 |
| PL377354A1 (pl) | 2006-01-23 |
| JP4733986B2 (ja) | 2011-07-27 |
| NO20053624D0 (no) | 2005-07-26 |
| AU2003292436B2 (en) | 2009-07-30 |
| RU2005123807A (ru) | 2006-01-20 |
| US20060046985A1 (en) | 2006-03-02 |
| NZ540729A (en) | 2008-03-28 |
| EP1578748B1 (en) | 2010-09-15 |
| IS7892A (is) | 2005-06-13 |
| US7414045B2 (en) | 2008-08-19 |
| CN100343253C (zh) | 2007-10-17 |
| BR0317749A (pt) | 2005-11-22 |
| KR20050087865A (ko) | 2005-08-31 |
| JP2006513200A (ja) | 2006-04-20 |
| NO20053624L (no) | 2005-09-26 |
| US20080176869A1 (en) | 2008-07-24 |
| WO2004058757A1 (en) | 2004-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050593A2 (en) | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors | |
| US7820680B2 (en) | HIV integrase inhibitors | |
| JP4252797B2 (ja) | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 | |
| ES2543711T3 (es) | Compuestos de pirrolo-triazin anilina útiles como inhibidores de quinasa | |
| ES2291642T3 (es) | Hidroxinaftiridinoncarboxamidas utiles como inhibidores de la integrasa de vih. | |
| ES2274913T3 (es) | Aza y poliaza-naftalenil carboxamidas utiles como inhibidores de vih integrada. | |
| AU2002238947B2 (en) | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | |
| HRP960321A2 (en) | Chemical compounds | |
| KR20070026414A (ko) | Ｈｉｖ 인테그라제 억제제 | |
| JP2004510819A (ja) | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 | |
| JP2008501021A (ja) | Ｈｉｖインテグラーゼ阻害剤としての二環式複素環 | |
| CA2622639C (en) | Hiv integrase inhibitors | |
| WO2018118829A1 (en) | Heterocyclic compounds as hiv protease inhibitors | |
| JP2017537982A (ja) | インドール及びアザインドール誘導体、並びに神経変性疾患におけるそれらの使用 | |
| CA2542047A1 (en) | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | |
| WO2023230612A1 (en) | Heterocyclic pad4 inhibitors | |
| ZA200504853B (en) | Tetrahydro-4h-Pyrido[1,2-A]Pyrimidines and related compound useful as HIV integrase inhibitors | |
| MXPA06010252A (en) | Hiv integrase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| OBST | Application withdrawn | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20091217 Year of fee payment: 7 |